---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-21-005373"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2021-08-02T23:59:59+00:00"
generated_at: "2026-06-29T23:57:59.308888+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corvus Q2 net loss $11.8M; discontinues COVID-19 trial, cuts cash burn guidance

## Summary
- Cash, equivalents and marketable securities $66.5M at June 30, 2021, up from $44.3M at Dec 31, 2020.
- Net loss $11.8M for Q2 2021 vs $10.6M in Q2 2020; R&D expenses $9.1M (up $1.2M YoY).
- Discontinued Phase 3 mupadolimab COVID-19 trial in July 2021 (no safety/efficacy issue); full-year cash burn guidance cut ~$11M to $35-37M.
- Enrolling Phase 1b/2 trial of mupadolimab plus pembrolizumab in HPV+ oropharyngeal cancer; results expected by year-end 2021.
- Angel Pharmaceuticals filed IND in China for CPI-818 Phase 2 in T-cell lymphomas; ciforadenant Phase 2 RCC trial planned with Kidney Cancer Consortium.

## SEC filing metadata
- accession: 0001171843-21-005373
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2021-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184321005373/0001171843-21-005373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184321005373/f8k_080221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-21-005373
- JSON: https://secwatch.observer/filing/0001171843-21-005373.json
- Plain text: https://secwatch.observer/filing/0001171843-21-005373.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.